| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
107,850,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
83,566 |
292,093 |
389,947 |
579,547 |
| Total Sell Value |
$5,551,567 |
$19,764,414 |
$24,649,785 |
$29,657,922 |
| Total People Sold |
4 |
6 |
6 |
8 |
| Total Sell Transactions |
12 |
35 |
47 |
81 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hopfner Robert Lorne |
Director |
– • – |
2021-01-15 |
4 |
AS |
$25.74 |
$687,846 |
I/I |
(26,677) |
1,938,417 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-14 |
4 |
AS |
$25.88 |
$386,078 |
I/I |
(14,918) |
1,965,094 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-13 |
4 |
AS |
$25.90 |
$755,313 |
I/I |
(29,110) |
1,980,012 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-12 |
4 |
AS |
$26.35 |
$489,871 |
I/I |
(18,567) |
2,009,122 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-11 |
4 |
AS |
$25.42 |
$1,313,764 |
I/I |
(49,666) |
2,027,689 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-01-11 |
4 |
AS |
$25.38 |
$65,527 |
D/D |
(2,500) |
77,899 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-01-11 |
4 |
OE |
$1.79 |
$4,475 |
D/D |
2,500 |
80,399 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-08 |
4 |
AS |
$26.43 |
$1,079,549 |
I/I |
(40,612) |
2,077,355 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-07 |
4 |
AS |
$27.75 |
$1,344,887 |
I/I |
(47,580) |
2,117,967 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-01-06 |
4 |
AS |
$29.24 |
$1,695,841 |
I/I |
(57,420) |
2,165,547 |
|
- |
|
| Fairman Jeff |
VP, Research |
• – – |
2020-12-29 |
4 |
OE |
$1.79 |
$1,325 |
D/D |
740 |
1,408 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2020-12-28 |
4 |
OE |
$1.79 |
$9,845 |
D/D |
5,500 |
578,691 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2020-12-21 |
4 |
AS |
$28.42 |
$433,141 |
D/D |
(15,000) |
573,191 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2020-12-21 |
4 |
OE |
$1.79 |
$26,850 |
D/D |
15,000 |
588,191 |
|
- |
|
| Coulter James G |
Former 10% Owner |
– – – |
2020-12-15 |
4 |
S |
$32.46 |
$2,664,691 |
I/I |
(81,979) |
5,074,574 |
|
- |
|
| Newell William J |
Director |
– • – |
2020-12-09 |
4 |
A |
$1.29 |
$28,674 |
D/D |
22,228 |
66,684 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-10-08 |
4 |
S |
$50.69 |
$8,498,065 |
I/I |
(167,661) |
5,001,593 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-10-07 |
4 |
S |
$50.95 |
$5,023,527 |
I/I |
(98,597) |
5,169,254 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-10-01 |
4 |
S |
$48.64 |
$776,705 |
I/I |
(15,967) |
0 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-09-30 |
4 |
S |
$50.27 |
$6,265,871 |
I/I |
(124,656) |
5,283,818 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-09-29 |
4 |
S |
$52.08 |
$4,202,987 |
I/I |
(80,707) |
5,408,474 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-06-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,489,181 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-16 |
4 |
B |
$16.00 |
$15,000,000 |
I/I |
937,500 |
5,156,553 |
1.5 |
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
I/I |
4,219,053 |
4,219,053 |
|
- |
|
| Emster Kurt Von |
Director |
– • – |
2020-06-16 |
4 |
B |
$16.00 |
$200,000 |
I/I |
12,500 |
4,168,718 |
2.1 |
- |
|
363 Records found
|
|
Page 14 of 15 |
|
|
